Mitomycin C in the form of eye drops in a concentration of 0 4 mg/ml (0-04%) was used as adjunctive treatment for primary and recurrent pterygium after surgical excision. The study was concurrent in nature and consisted of 32 pterygia in 30 patients and was done over a period of 36 months. The object was to observe the effect of mitomycin C drops on pterygium recurrence Encouraged by the results shown by Japanese and other workers,'"2' we undertook this concurrent study of mitomycin C 0 4 mg/ml (0 04%) drops used four times a day from first postoperative day for 2 weeks after pterygium excision by the bare sclera technique to determine its effect on pterygium recurrence. To the best of our knowledge this is the first study to be published from a country where pterygium is such an endemic problem.
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Abstract Mitomycin C in the form of eye drops in a concentration of 0 4 mg/ml (0-04%) was used as adjunctive treatment for primary and recurrent pterygium after surgical excision. The study was concurrent in nature and consisted of 32 pterygia in 30 patients and was done over a period of 36 months. The object was to observe the effect of mitomycin C drops on pterygium recurrence after surgical excision. Fifteen eyes of 15 patients were treated with 'bare sclera technique' for pterygium excision. Nine patients showed recurrence occurring within first 6 months of surgery. On the other hand 17 eyes of 15 patients after bare sciera pterygium excision received mitomycin 0 4 mg/ml (0.04%) eye drops four times a day for 2 weeks from first postoperative day. There was no recurrence of pterygium in this group. Follow up time for these cases ranged from [13] [14] [15] [16] [17] [18] [19] Encouraged by the results shown by Japanese and other workers,'"2' we undertook this concurrent study of mitomycin C 0 4 mg/ml (0 04%) drops used four times a day from first postoperative day for 2 weeks after pterygium excision by the bare sclera technique to determine its effect on pterygium recurrence. To the best of our knowledge this is the first study to be published from a country where pterygium is such an endemic problem.
Materials and methods
Patients attending the outpatient clinic with pterygium requiring surgery were allocated to two groups at random.
Pterygium occurs all over the world but it is more common in subtropical and tropical areas. It is one of the common corneal disorders seen in Saudi Arabia. The stimulus which causes a pterygium to grow is excessive exposure to ultraviolet sunlight. Other agents that give rise to chronic irritation of the conjunctiva such as air pollution, dust, and wind have also been mentioned as determining factors.12
Treatment of choice for pterygium is surgical excision. However, the recurrence rate of pterygium after excision is quite high (30-50%)6 unless something is done at the time of excision.
The use of postoperative , irradiation7" has been reported to lower the incidence of recurrence to less than 5% but has led to further complications such as scleral ulceration and cataract formation. It also requires special centres and management for referring such patients.
Argon laser has been used to control very early blood vessel growth in the sclera and limbus to prevent pterygium recurrence following surgery. 12 Though in the past many workers have shown good results with use of topical thiotepa (triethylene thiophosphoramide),'>'" a radiomimetic alkylating agent, one of the problems that occurs in darkly pigmented patients is depigmentation of the lids.
Conjunctival autograft transplantation has been used successfully by some workers7 18 after pterygium excision to reduce the incidence of recurrence. But our local experience with free conjunctival grafts from the superotemporal bulbar conjunctiva of the same eye to resurface the exposed sclera has been disappointing GROUP I Patients in this group were operated on by the bare sclera technique. After preparing and draping the eye in normal sterile fashion, the lids were opened using a rigid eye speculum. Surface anaesthesia was achieved with 1% amethocaine drops. Lignocaine, 0-2 ml of a 2% solution, with 1 
blemish occurred. Recurrence was considered if fibrovascular All patients were examined by slit-lamp growth of a similar nature to that present pre-biomicroscopy with charting of visual acuity pre caesopitosus. Mitomycin C is present in a blueviolet crystalline powder and is soluble in water. Following reconstitution of the powder for topical use, mitomycin 0 4 mg/ml has a pH of 6-8, and is stable for 2 weeks when refrigerated at 2-8°C. When used in topical form, our series of 17 eyes of 15 patients showed no recurrence at all -a 100% success rate. The minimum follow up period for these patients was 13 months. This is very significant as most of our recurrences in the first group occurred during the first 6 months (first case at 10 months). Our patients showed only exaggerated conjunctival injection with delayed wound healing for 3-4 weeks, but this settled down with no significant consequences.
We think this form of adjunctive therapy is superior in comparison with the other modes of treatment such as topical thiotepa drops,'4 16 radiation,7 10 and laser treatment.'2 Even compared with conjunctival autografts, this technique is simpler as it is performed only under local anaesthesia thus avoiding the risk of retrobulbar anaesthesia in young patients.
